Challenges in Translating from Bench to Bed-Side: Pro-Angiogenic Peptides for Ischemia Treatment

• Published in: Molecules (Basel, Switzerland) Vol. 24; no. 7; p. 1219
• Main Authors: Petrak, Karel, Vissapragada, Ravi, Shi, Siyu, Siddiqui, Zain, Kim, Ka Kyung, Sarkar, Biplab, Kumar, Vivek A.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.03.2019; MDPI
• Subjects: Adenoviruses; Amputation; Angiogenesis; Angiogenic Proteins - therapeutic use; Animals; Atherosclerosis; Biodistribution; Clinical trials; Communication; development; Disease Models, Animal; Drug Discovery; Drug therapy; Fibroblasts; Gene expression; Growth factors; Humans; Ischemia; Ischemia - drug therapy; Neovascularization, Physiologic - drug effects; Patients; peptide; Pharmacokinetics; Success; therapeutic; translation; Translational Research, Biomedical; Ulcers; therapeutic; translation; development; peptide; angiogenesis; ischemia
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules24071219

We describe progress and obstacles in the development of novel peptide-hydrogel therapeutics for unmet medical needs in ischemia treatment, focusing on the development and translation of therapies specifically in peripheral artery disease (PAD). Ischemia is a potentially life-threatening complication in PAD, which affects a significant percentage of the elderly population. While studies on inducing angiogenesis to treat PAD were started two decades ago, early results from animal models as well as clinical trials have not yet been translated into clinical practice. We examine some of the challenges encountered during such translation. We further note the need for sustained angiogenic effect involving whole growth factor, gene therapy and synthetic growth factor strategies. Finally, we discuss the need for tissue depots for de novo formation of microvasculature. These scaffolds can act as templates for neovasculature development to improve circulation and healing at the preferred anatomical location.